Literature DB >> 31308151

White matter hyperintensity load on stroke recurrence and mortality at 1 year after ischemic stroke.

Wi-Sun Ryu1, Dawid Schellingerhout1, Keun-Sik Hong1, Sang-Wuk Jeong1, Min Uk Jang1, Man-Seok Park1, Kang-Ho Choi1, Joon-Tae Kim1, Beom Joon Kim1, Jun Lee1, Jae-Kwan Cha1, Dae-Hyun Kim1, Hyun-Wook Nah1, Soo Joo Lee1, Jae Guk Kim1, Yong-Jin Cho1, Byung-Chul Lee1, Kyung-Ho Yu1, Mi Sun Oh1, Jong-Moo Park1, Kyusik Kang1, Kyung Bok Lee1, Tai Hwan Park1, Sang-Soon Park1, Juneyoung Lee1, Hee-Joon Bae1, Dong-Eog Kim2.   

Abstract

OBJECTIVE: To define the role and risks associated with white matter hyperintensity (WMH) load in a stroke population with respect to recurrent stroke and mortality after ischemic stroke.
METHODS: A total of 7,101 patients at a network of university hospitals presenting with ischemic strokes were followed up for 1 year. Multivariable Cox proportional hazards model and competing risk analysis were used to examine the independent association between quartiles of WMH load and stroke recurrence and mortality at 1 year.
RESULTS: Overall recurrent stroke risk at 1 year was 6.7%/y, divided between 5.6%/y for recurrent ischemic and 0.5%/y for recurrent hemorrhagic strokes. There was a stronger association between WMH volume and recurrent hemorrhagic stroke by quartile (hazard ratio [HR] 7.32, 14.12, and 33.52, respectively) than for ischemic recurrence (HR 1.03, 1.37, and 1.61, respectively), but the absolute incidence of ischemic recurrence by quartile was higher (3.8%/y, 4.5%/y, 6.3%/y, and 8.2%/y by quartiles) vs hemorrhagic recurrence (0.1%/y, 0.4%/y, 0.6%/y, and 1.3%/y). All-cause mortality (10.5%) showed a marked association with WMH volume (HR 1.06, 1.46, and 1.60), but this was attributable to nonvascular rather than vascular causes.
CONCLUSIONS: There is an association between WMH volume load and stroke recurrence, and this association is stronger for hemorrhagic than for ischemic stroke, although the absolute risk of ischemic recurrence remains higher. These data should be helpful to practitioners seeking to find the optimal preventive/treatment regimen for poststroke patients and to individualize risk-benefit ratios.
© 2019 American Academy of Neurology.

Entities:  

Year:  2019        PMID: 31308151     DOI: 10.1212/WNL.0000000000007896

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes.

Authors:  Wi-Sun Ryu; Dawid Schellingerhout; Keun-Sik Hong; Sang-Wuk Jeong; Beom Joon Kim; Joon-Tae Kim; Kyung Bok Lee; Tai Hwan Park; Sang-Soon Park; Jong-Moo Park; Kyusik Kang; Yong-Jin Cho; Hong-Kyun Park; Byung-Chul Lee; Kyung-Ho Yu; Mi Sun Oh; Soo Joo Lee; Jae Guk Kim; Jae-Kwan Cha; Dae-Hyun Kim; Jun Lee; Moon-Ku Han; Man Seok Park; Kang-Ho Choi; Matthias Nahrendorf; Juneyoung Lee; Hee-Joon Bae; Dong-Eog Kim
Journal:  Ann Neurol       Date:  2021-10-05       Impact factor: 11.274

2.  Total small vessel disease burden and functional outcome in patients with ischemic stroke.

Authors:  Wi-Sun Ryu; Sang-Wuk Jeong; Dong-Eog Kim
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

3.  Association of ischemic stroke onset time with presenting severity, acute progression, and long-term outcome: A cohort study.

Authors:  Wi-Sun Ryu; Keun-Sik Hong; Sang-Wuk Jeong; Jung E Park; Beom Joon Kim; Joon-Tae Kim; Kyung Bok Lee; Tai Hwan Park; Sang-Soon Park; Jong-Moo Park; Kyusik Kang; Yong-Jin Cho; Hong-Kyun Park; Byung-Chul Lee; Kyung-Ho Yu; Mi Sun Oh; Soo Joo Lee; Jae Guk Kim; Jae-Kwan Cha; Dae-Hyun Kim; Jun Lee; Moon-Ku Han; Man Seok Park; Kang-Ho Choi; Juneyoung Lee; Jeffrey L Saver; Eng H Lo; Hee-Joon Bae; Dong-Eog Kim
Journal:  PLoS Med       Date:  2022-02-04       Impact factor: 11.069

4.  Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus.

Authors:  Seung Eun Lee; Hyewon Nam; Han Seok Choi; Hoseob Kim; Dae-Sung Kyoung; Kyoung-Ah Kim
Journal:  Diabetes Metab J       Date:  2022-02-08       Impact factor: 5.893

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.